Brief: Ose Immunotherapeutics Announces Positive Clinical Progress For Late-Stage Proprietary Cancer Vaccine
11/12/2024 18:27
Dec 11 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE CLINICAL
PROGRESS FOR
LATE-STAGE PROPRIETARY CANCER VACCINE TEDOPI®
* OSE IMMUNOTHERAPEUTICS SA - PHASE 2 ENROLLMENT FOR TEDOPI
IN
NSCLC EXPECTED Q1 2025
Source text: ID:nGNX4Vdktk
Further company coverage: OSE.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO